CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple negative breast...
Phase 1
Dallas, Texas, United States and 5 other locations
of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...
Phase 1, Phase 2
Dallas, Texas, United States and 46 other locations
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemothe ...
Phase 2
Dallas, Texas, United States and 8 other locations
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo a...
Phase 3
Dallas, Texas, United States and 70 other locations
in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...
Phase 2
Dallas, Texas, United States and 21 other locations
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...
Phase 1, Phase 2
Dallas, Texas, United States and 49 other locations
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Dallas, Texas, United States and 216 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Dallas, Texas, United States and 226 other locations
Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") re ...
Phase 2
Dallas, Texas, United States and 3 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Dallas, Texas, United States and 506 other locations
Clinical trials
Research sites
Resources
Legal